Drugs / rogocekib
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05732103 | Apr 2023 → Jun 2028 expected | acute myeloid leukemia, myelodysplastic syndrome | Chordia Therapeutics, Inc. | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rogocekib | “Rogocekib (development name CTX-712) is a first-in-class, orally available, highly potent, and selective small-molecule inhibitor of CDC2-like kinase, a key regulator of the...” PMID 41056522 ↗ Jan 2026 |
| Known as | CTX-712 | “Rogocekib (development name CTX-712) is a first-in-class, orally available, highly potent, and selective small-molecule inhibitor of CDC2-like kinase, a key regulator of the...” PMID 41056522 ↗ Jan 2026 |
| Action | Inhibit | “small-molecule inhibitor of CDC2-like kinase” PMID 41056522 ↗ Jan 2026 |
| Modality | Small molecule | “small-molecule inhibitor” PMID 41056522 ↗ Jan 2026 |
| Route | Oral | “oral administration” NCT05732103 ↗ |